Max Masucci
Stock Analyst at TD Cowen
(0.21)
# 4,442
Out of 5,143 analysts
22
Total ratings
16.67%
Success rate
-30.77%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $39.77 | +81.04% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $22.65 | +10.38% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $95.40 | -44.44% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $75.35 | +26.08% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $5.70 | +215.79% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $13.02 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $3.34 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $2.84 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $0.79 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $4.36 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.13 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.26 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $122.90 | +282.42% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.69 | +577.51% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $103.45 | +40.16% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $39.77
Upside: +81.04%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $22.65
Upside: +10.38%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $95.40
Upside: -44.44%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $75.35
Upside: +26.08%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $5.70
Upside: +215.79%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $13.02
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.34
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.84
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.79
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.36
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.13
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.26
Upside: -
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $122.90
Upside: +282.42%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $3.69
Upside: +577.51%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $103.45
Upside: +40.16%